Encapsulation and controlled release of antioxidants and vitamins

Delivery and Controlled Release of Bioactives in Foods and Nutraceuticals

Volumn , Issue , 2008, Pages 297-330

  Sabliov, Cristina M ^a   Astete, C E ^a  

^a LOUISIANA STATE UNIVERSITY AGRICULTURAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CONTROLLED RELEASE;

EID: 84872834275     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1533/9781845694210.3.297     Document Type: Chapter

References (200)

1. Halliwell B., Gutteridge J.N.C. The definition and measurement of antioxidants in biological systems. Free Radical Bio Med 1995, 18(1):125-126.
2. Halliwell B. Antioxidant defence mechanisms: from the beginning to the end (of the beginning). Free Radical Research 1999, 31(4):261-272.
3. Young I.S., Woodside J.V. Antioxidants in health and disease. Journal of Clinical Pathology 2001, 54(3):176-186.
4. Knight J.A. Review: Free radicals, antioxidants, and the immune system. Annals of Clinical and Laboratory Science 2000, 30(2):145-158.
5. Draper H.H., Draper H.H., Bird R.P. Antioxidants and cancer. Journal of Agricultural and Food Chemistry 1984, 32:433-435.
6. Zhang Y.H., Kramer T.R., Taylor P.R., Li J.Y., Blot W.J., Brown C.C., Guo W., Dawsey S.M., Li B. Possible immunologic involvement of antioxidants in cancer prevention. The American Journal of Clinical Nutrition 1995, 62(6 Suppl):1477S-1482S.
7. Vina J., Lloret A., Orti R., Alonso D. Molecular bases of the treatment of Alzheimer's disease with antioxidants: prevention of oxidative stress. Molecular Aspects of Medicine 2004, 25(1-2):117-123.
8. Pani G., Colavitti R., Bedogni B., Fusco S., Ferraro D., Borrello S., Galeotti T. Mitochondrial superoxide dismutase: a promising target for new anticancer therapies. Current Medicinal Chemistry - Anti-Inflammatory and Anti-Allergy Agents 2004, 11(10):1299-1308.
9. Hensley K., Robinson K.A., Gabbita S.P., Salsman S., Floyd R.A. Reactive oxygen species, cell signaling, and cell injury. Free Radical Bio Med 2000, 28(10):1456-1462.
10. Taylor A., Jacques P.F., Epstein E.M. Relations among aging, antioxidant status, and cataract. The American Journal of Clinical Nutrition 1995, 62(6 Suppl):1439S-1447S.
11. Halliwell B. Lipid peroxidation, antioxidants and cardiovascular disease: how should we move forward?. Cardiovascular Research 2000, 47(3):410-418.
12. Hazen S.L. Oxidation and atherosclerosis. Free Radical Bio Med 2000, 28(12):1683-1684.
13. Adlam V.J., Harrison J.C., Porteous C.M., James A.M., Smith R.A.J., Murphy M.P., Sammut I.A. Targeting an antioxidant to mitochondria decreases cardiac ischemia-reperfusion injury. FASEB J 2005, 19(9):1088-1095.
14. Bergendi L., Benes L., Durackova Z., Ferencik M. Chemistry, physiology and pathology of free radicals. Life Sciences 1999, 65(18-19):1865-1874.
15. Azzi A., Davies K.J., Kelly F. Free radical biology - terminology and critical thinking. FEBS Letters 2004, 558(1-3):3-6.
16. Kojda G., Harrison D. Interactions between NO and reactive oxygen species: pathophysiological importance in atherosclerosis, hypertension, diabetes and heart failure. Cardiovascular Research 1999, 43(3):562-571.
17. Nishikawa T., Edelstein D., Du X.L., Yamagishi S., Matsumura T., Kaneda Y., Yorek M.A., Beebe D., Oates P.J., Hammes H.P., Giardino I., Brownlee M. Normalizing mitochondrial superoxide production blocks three pathways of hyper-glycaemic damage. Nature 2000, 404(6779):787-790.
18. Ferrari C.K. Functional foods, herbs and nutraceuticals: towards biochemical mechanisms of healthy aging. Biogerontology 2004, 5(5):275-289.
19. Vitaglione P., Morisco F., Caporaso N., Fogliano V. Dietary antioxidant compounds and liver health. Critical Reviews in Food Science and Nutrition 2004, 44(7-8):575-586.
20. Higuera-Ciapara I., Felix-Valenzuela L., Goycoolea F.M. Astaxanthin: a review of its chemistry and applications. Critical Reviews in Food Science and Nutrition 2006, 46(2):185-196.
21. Cutler R.G. Oxidative stress profiling: Part I. Its potential importance in the optimization of human health. Annals of the New York Academy of Sciences 2005, 1055:93-135.
22. Chisolm G.M., Steinberg D. The oxidative modification hypothesis of atherogenesis: an overview. Free Radical Biol Med 2000, 28(12):1815-1826.
23. Yang T.T.C., Devaraj S., Jialal I. Oxidative stress and atherosclerosis. Journal of Clinical Ligand Assay 2001, 24(1):13-24.
24. Albertini R., Moratti R., De Luca G. Oxidation of low-density lipoprotein in atherosclerosis from basic biochemistry to clinical studies. Current Molecular Medicine 2002, 2(6):579-592.
25. Allen R.G., Tresini M. Oxidative stress and gene regulation. Free Radical Biol Med 2000, 28(3):463-499.
26. Machlin L.J., Bendich A. Free radical tissue damage: protective role of antioxidant nutrients. FASEB J 1987, 1(6):441-445.
27. Willcox J.K., Ash S.L., Catignani G.L. Antioxidants and prevention of chronic disease. Critical Reviews in Food Science and Nutrition 2004, 44(4):275-295.
28. Nohl H., Gille L. Lysosomal ROS formation. Redox Report 2005, 10(4):199-205.
29. Babior B.M. Superoxide: a two-edged sword. Brazilian Journal of Medical and Biological Research 1997, 30(2):141-155.
30. Turrens J.F. Mitochondrial formation of reactive oxygen species. The Journal of Physiology 2003, 552(Pt 2):335-344.
31. Dotan Y., Lichtenberg D., Pinchuk I. Lipid peroxidation cannot be used as a universal criterion of oxidative stress. Progress in Lipid Research 2004, 43(3):200-227.
32. Sagin F.G., Sozmen E.Y. Anti-inflammatory effects of dietary anti-oxidants. Current Medicinal Chemistry - Anti-Inflammatory and Anti-Allergy Agents 2004, 3(1):19-30.
33. Lachance P.A., Nakat Z., Jeong W.S. Antioxidants: an integrative approach. Nutr 2001, 17(10):835-838.
34. Brigelius-Flohe R., Traber M.G. Vitamin E: function and metabolism. FASEB J 1999, 13(10):1145-1155.
35. Wagner K.H., Isnardy B., Elmadfa I. Gamma- and delta -tocopherols are more effective than alpha-tocopherol on the autoxidation of a 10% rapeseed oil triacylglycerol-in-water emulsion with and without a radical initiator. European Journal of Lipid Science and Technology 2004, 106(1):44-51.
36. Wagner K.H., Kamal-Eldin A., Elmadfa I. Gamma-tocopherol - an underestimated vitamin?. Annals of Nutrition & Metabolism 2004, 48(3):169-188.
37. Jiang Q., Christen S., Shigenaga M.K., Ames B.N. Gamma-tocopherol, the major form of vitamin E in the US diet, deserves more attention. The American Journal of Clinical Nutrition 2001, 74(6):714-722.
38. Leonard S.W., Paterson E., Atkinson J.K., Ramakrishnan R., Cross C.E., Traber M.G. Studies in humans using deuterium-labeled alpha- and gamma-tocopherols demonstrate faster plasma gamma-tocopherol disappearance and greater gamma-metabolite production. Free Radical Biol Med 2005, 38(7):857-866.
39. Berman K., Brodaty H. Tocopherol (vitamin E) in Alzheimer's disease and other neurodegenerative disorders. CNS Drugs 2004, 18(12):807-825.
40. Cohn W. Bioavailability of vitamin E. European Journal of Clinical Nutrition 1997, 51:S80-S85.
41. Wang X., Quinn P.J. Vitamin E and its function in membranes. Progress in Lipid Research 1999, 38(4):309-336.
42. Kaul N., Devaraj S., Jialal I. Alpha-tocopherol and atherosclerosis. Experimental Biology and Medicine 2001, 226(1):5-12.
43. Meydani S.N., Wud, Santos M.S., Hayek M.G. Antioxidants and immune response in aged persons: overview of present evidence. The American Journal of Clinical Nutrition 1995, 62(6 Suppl):1462S-1476S.
44. Harris A., Devaraj S., Jialal I. Oxidative stress, alpha-tocopherol therapy, and atherosclerosis. Current Atherosclerosis Reports 2002, 4(5):373-380.
45. Upston J.M., Kritharides L., Stocker R. The role of vitamin E in atherosclerosis. Progress in Lipid Research 2003, 42(5):405-422.
46. Bramley P.M., Elmadfa A., Kafatos F.J., Kelly Y., Manios H.E., Roxborough W., Schuch P.J., Sheehy A., Wagner K.H. Review vitamin E. Journal of the Science of Food and Agricultural 2000, 80:913-938.
47. Wayner D.D.M., Burton G.W., Ingold K.U., Barclay L.R.C., Locke S.J. The relative contribution of vitamin E, urate, ascorbate and proteins to the total peroxyl radical-trapping antioxidant activity of human blood plasma. Biochimica et Biophysica Acta (BBA) - General Subjects 1987, 924(3):408-419.
48. Thomas S.R., Stocker R. Molecular action of vitamin E in lipoprotein oxidation: implications for atherosclerosis. Free Radical Biol Med 2000, 28(12):1795-1805.
49. Jialal I., Devaraj S. Scientific evidence to support a vitamin E and heart disease health claim: research needs. The Journal of Nutrition 2005, 135(2):348-353.
50. Crane F.L. Biochemical functions of coenzyme Q10. Journal of the American College of Nutrition 2001, 20(6):591-598.
51. Quinn P.J., Fabisiak J.P., Kagan V.E. Expansion of antioxidant function of vitamin E by coenzyme Q. Biofactors 1999, 9(2-4):149-154.
52. Kaikkonen J., Tuomainen T.P., Nyyssonen K., Salonen J.T. Coenzyme Q10: absorption, antioxidative properties, determinants, and plasma levels. Free Radical Research 2002, 36(4):389-397.
53. Nohl H., Staniek K., Kozlov A.V., Gille L. The biomolecule ubiquinone exerts a variety of biological functions. Biofactors 2003, 18(1-4):23-31.
54. Bhagavan H.N., Chopra R.K. Coenzyme Q10: absorption, tissue uptake, metabolism and pharmacokinetics. Free Radical Research 2006, 40(5):445-453.
55. Laaksonen R., Riihimaki A., Laitila J., Martensson K., Tikkanen M.J., Himberg J.J. Serum and muscle tissue ubiquinone levels in healthy subjects. The Journal of Laboratory and Clinical Medicine 1995, 125(4):517-521.
56. Zita C., Overvad K., Mortensen S.A., Sindberg C.D., Moesgaard S., Hunter D.A. Serum coenzyme Q10 concentrations in healthy men supplemented with 30 mg or 100 mg coenzyme Q10 for two months in a randomised controlled study. Biofactors 2003, 18(1-4):185-193.
57. Turunen M., Sindelar P., Dallner G. Induction of endogenous coenzyme Q biosynthesis by administration of peroxisomal inducers. Biofactors 1999, 9(2-4):131-139.
58. Overvad K., Diamant B., Holm L., Holmer G., Mortensen S.A., Stender S. Coenzyme Q10 in health and disease. European Journal of Clinical Nutrition 1999, 53(10):764-770.
59. Sarter B. Coenzyme Q10 and cardiovascular disease: a review. The Journal of Cardiovascular Nursing 2002, 16(4):9-20.
60. Langsjoen P.H., Langsjoen A.M. Overview of the use of CoQ10 in cardiovascular disease. Biofactors 1999, 9(2-4):273-284.
61. Beal M.F. Coenzyme Q10 as a possible treatment for neurodegenerative diseases. Free Radical Research 2002, 36(4):455-460.
62. Galati G., O'brien P.J. Cytoprotective and anticancer properties of coenzyme Q versus capsaicin. Biofactors 2003, 18(1-4):195-205.
63. Conklin K.A. Coenzyme Q10 for prevention of anthracycline-induced cardiotoxicity. Integrative Cancer Therapies 2005, 4(2):110-130.
64. Mortensen S.A. Overview on coenzyme Q10 as adjunctive therapy in chronic heart failure. Rationale, design and end-points of Q-symbio - a multinational trial. Biofactors 2003, 18(1-4):79-89.
65. Genova M.L., Pich M.M., Biondi A., Bernacchia A., Falasca A., Bovina C., Formiggini G., Parenti Castelli G., Lenaz G. Mitochondrial production of oxygen radical species and the role of Coenzyme Q as an antioxidant. Experimental Biology and Medicine 2003, 228(5):506-513.
66. Pich M.M., Castagnoli A., Biondi A., Bernacchia A., Tazzari P.L., D'aurelio M., Castelli G.P., Formiggini G., Conte R., Bovina C., Lenaz G. Ubiquinol and a Coenzyme Q reducing system protect platelet mitochondrial function of transfusional buffy coats from oxidative stress. Free Radical Res 2002, 36(4):429-436.
67. Sandor P.S., Di Clemente L., Coppola G., Saenger U., Fumal A., Magis D., Seidel L., Agosti R.M., Schoenen J. Efficacy of coenzyme Q10 in migraine prophylaxis: a randomized controlled trial. Neurology 2005, 64(4):713-715.
68. Miles M.V., Horn P., Miles L., Tang P., Steele P., Degrauw T. Bio-equivalence of coenzyme Q(10) from over-the-counter supplements. Nutrition Research 2002, 22(8):919-929.
69. Zaghloul A.A., Gurley B., Khan M., Bhagavan H., Chopra R., Reddy I. Bioavailability assessment of oral coenzyme Q10 formulations in dogs. Drug Development and Industrial Pharmacy 2002, 28(10):1195-1200.
70. Tikhaze A.K., Konovalova G.G., Lankin V.Z., Kaminnyi A.I., Kaminnaja V.I., Ruuge E.K., Kukharchuk V.V. Effect of ubiquinone Q(10) and antioxidant vitamins on free radical oxidation of phospholipids in biological membranes of rat liver. Bulletin of Experimental Biology and Medicine 2005, 140(2):181-183.
71. Hughes D.A. Dietary carotenoids and human immune function. Nutrition 2001, 17(10):823-827.
72. Young A.J., Lowe G.M. Antioxidant and prooxidant properties of carotenoids. Archives of Biochemistry and Biophysics 2001, 385(1):20-27.
73. Cooke M.S., Evans M.D., Mistry N., Lunec J. Role of dietary antioxidants in the prevention of in vivo oxidative DNA damage. Nutrition Research Reviews 2002, 15(1):19-41.
74. Zheng W., Wang S.Y. Antioxidant activity and phenolic compounds in selected herbs. J Agric Food Chem 2001, 49(11):5165-5170.
75. Di Carlo G., Mascolo N., Izzo A.A., Capasso F. Flavonoids: old and new aspects of a class of natural therapeutic drugs. Life Sciences 1999, 65(4):337-353.
76. Tapiero H., Tew K.D., Ba G.N., Mathe G. Polyphenols: do they play a role in the prevention of human pathologies?. Biomedicine & Pharmacotherapy 2002, 56(4):200-207.
77. Pietta P.G. Flavonoids as antioxidants. Journal of Natural Products 2000, 63(7):1035-1042.
78. Van Acker S.A., Van Den Berg D.J., Tromp M.N., Griffioen D.H., Van Bennekom W.P., Van Der Vijgh W.J., Bast A. Structural aspects of antioxidant activity of flavonoids. Free Radical Biol Med 1996, 20(3):331-342.
79. Hollman P.C.H. Absorption, bioavailability, and metabolism of flavonoids. Pharmaceutical Biology 2004, 42:74-83.
80. Cotelle N., Bernier J.L., Catteau J.P., Pommery J., Wallet J.C., Gaydou E.M. Antioxidant properties of hydroxy-flavones. Free Radical Biol Med 1996, 20(1):35-43.
81. Croft K.D. The chemistry and biological effects of flavonoids and phenolic acids. Annals of the New York Academy of Sciences 1998, 854:435-442.
82. Karakaya S. Bioavailability of phenolic compounds. Critical Reviews in Food Science and Nutrition 2004, 44(6):453-464.
83. Silva M.M., Santos M.R., Caroco G., Rocha R., Justino G., Mira L. Structure-antioxidant activity relationships of flavonoids: a re-examination. Free Radical Res 2002, 36(11):1219-1227.
84. Galati G., O'brien P.J. Potential toxicity of flavonoids and other dietary phenolics: significance for their chemopreventive and anticancer properties. Free Radical Biol Med 2004, 37(3):287-303.
85. Neuhouser M.L. Flavonoids and cancer prevention: what is the evidence in humans?. Pharmaceutical Biology 2004, 42:36-45.
86. Kaur C., Kapoor H.C. Antioxidants in fruits and vegetables - the millennium's health. International Journal of Food Science and Technology 2001, 36(7):703-725.
87. Kondratyuk T.P., Pezzuto J.M. Natural product polyphenols of relevance to human health. Pharmaceutical Biology 2004, 42:46-63.
88. Jeong W.S., Kong A.N.T. Biological properties of monomeric and polymeric catechins: green tea catechins and procyanidins. Pharmaceutical Biology 2004, 42:84-93.
89. Carr A.C., Frei B. Toward a new recommended dietary allowance for vitamin C based on antioxidant and health effects in humans. The American Journal of Clinical Nutrition 1999, 69(6):1086-1107.
90. Padayatty S.J., Katz A., Wang Y., Eck P., Kwon O., Lee J.H., Chen S., Corpe C., Dutta A., Dutta S.K., Levine M. Vitamin C as an antioxidant: evaluation of its role in disease prevention. Journal of the American College of Nutrition 2003, 22(1):18-35.
91. Coulter I.D., Hardy M.L., Morton S.C., Hilton L.G., Tuw, Valentine D., Shekelle P.G. Antioxidants vitamin C and vitamin E for the prevention and treatment of cancer. Journal of General Internal Medicine 2006, 21(7):735-744.
92. Bohm F., Edge R., Mcgarvey D.J., Truscott T.G. Beta-carotene with vitamins E and C offers synergistic cell protection against NOx. FEBS Letters 1998, 436(3):387-389.
93. Bauer K. Carnosine and homocarnosine, the forgotten, enigmatic peptides of the brain. Neurochemical Research 2005, 30(10):1339-1345.
94. Fontana M., Pinnen F., Lucente G., Pecci L. Prevention of peroxynitrite-dependent damage by carnosine and related sulphonamido pseudodipeptides. Cellular and Molecular Life Sciences 2002, 59(3):546-551.
95. Hipkiss A.R. Carnosine, a protective, anti-ageing peptide?. The International Journal of Biochemistry & Cell Biology 1998, 30(8):863-868.
96. Hipkiss A.R., Brownson C., Carrier M.J. Carnosine, the anti-ageing, antioxidant dipeptide, may react with protein carbonyl groups. Mechanisms of Ageing and Development 2001, 122(13):1431-1445.
97. Baran E.J. Metal complexes of carnosine. Biochemistry (Moscow) 2000, 65(7):789-797.
98. Boldyrev A.A. Protection of proteins from oxidative stress: a new illusion or a novel strategy?. Annals of the New York Academy of Sciences 2005, 1057:193-205.
99. Hipkiss A.R., Brownson C. Carnosine reacts with protein carbonyl groups: another possible role for the anti-ageing peptide?. Biogerontology 2000, 1(3):217-223.
100. Hipkiss A.R., Preston J.E., Himsworth D.T., Worthington V.C., Keown M., Michaelis J., Lawrence J., Mateen A., Allende L., Eagles P.A., Abbott N.J. Pluripotent protective effects of carnosine, a naturally occurring dipeptide. Annals of the New York Academy of Sciences 1998, 854:37-53.
101. Hipkiss A.R. Glycation, ageing and carnosine: are carnivorous diets beneficial?. Mechanisms of Ageing and Development 2005, 126(10):1034-1039.
102. Guiotto A., Calderan A., Ruzza P., Borin G. Carnosine and carnosine-related antioxidants: a review. Current Medicinal Chemistry - Anti-Inflammatory and Anti-Allergy Agents 2005, 12(20):2293-2315.
103. Nagai K., Niijima A., Yamano T., Otani H., Okumra N., Tsuruoka N., Nakai M., Kiso Y. Possible role of L-carnosine in the regulation of blood glucose through controlling autonomic nerves. Experimental Biology and Medicine 2003, 228(10):1138-1145.
104. Hipkiss A.R. Could carnosine suppress zinc-mediated proteasome inhibition and neurodegeneration? Therapeutic potential of a non-toxic but non-patentable dipeptide. Biogerontology 2005, 6(2):147-149.
105. Niki E., Noguchi N. Dynamics of antioxidant action of vitamin E. Accounts of Chemical Research 2004, 37(1):45-51.
106. Kwon S.S., Nam Y.S., Lee J.S., Ku B.S., Han S.H., Lee J.Y., Chang I.S. Preparation and characterization of coenzyme Q(10)-loaded PMMA nanoparticles by a new emulsification process based on microfluidization. Colloids and Surfaces A - Physicochemical and Engineering Aspects 2002, 210(1):95-104.
107. Chen L., Subirade M. Chitosan/beta-lactoglobulin core-shell nano-particles as nutraceutical carriers. Biomaterials 2005, 26(30):6041-6053.
108. Russell-Jones G.J. Use of targeting agents to increase uptake and localization of drugs to the intestinal epithelium. Journal of Drug Targeting 2004, 12(2):113-123.
109. Na K., Bum Lee T., Park K.H., Shin E.K., Lee Y.B., Choi H.K. Self-assembled nanoparticles of hydrophobically-modified polysaccharide bearing vitamin H as a targeted anti-cancer drug delivery system. Euopean Journal of Pharmaceutical Sciences 2003, 18(2):165-173.
110. Muro S., Cui X., Gajewski C., Murciano J.C., Muzykantov V.R., Koval M. Slow intracellular trafficking of catalase nanoparticles targeted to ICAM-1 protects endothelial cells from oxidative stress. American Journal of Physiology - Cell Physiology 2003, 285(5):C1339-C1347.
111. Shea T.B., Ortiz D., Nicolosi R.J., Kumar R., Watterson A.C. Nanosphere-mediated delivery of vitamin E increases its efficacy against oxidative stress resulting from exposure to amyloid beta. Journal of Alzheimer's Disease 2005, 7(4):297-301.
112. Duclairoir C., Orecchioni A.M., Depraetere P., Nakache E. Alpha-tocopherol encapsulation and in vitro release from wheat gliadin nanoparticles. J Microencapsul 2002, 19(1):53-60.
113. Zigoneanu I.G., Astete C.E., Monroe W.T., Sabliov C.M. Sustained release and antioxidant activity of alpha-tocopherol entrapped in Poly(D,L-lactide-co-glycolide) nanoparticles 2006, IFT Annual Meeting, Orlando, FL.
114. Chen C.C., Wagner G. Vitamin E nanoparticle for beverage applications 2004, 82(A11):1432-1437.
115. Anderson J.M., Shive M.S. Biodegradation and biocompatibility of PLA and PLGA microspheres. Advanced Drug Delivery Reviews 1997, 28(1):5-24.
116. Westesen K., Bunjes H., Hammer G., Siekmann B. Novel colloidal drug delivery systems. PDA Journal of Pharmaceutical Science and Technology/PDA 2001, 55(4):240-247.
117. Brigger I., Dubernet C., Couvreur P. Nanoparticles in cancer therapy and diagnosis. Advanced Drug Delivery Reviews 2002, 54(5):631-651.
118. Chorny M., Fishbein I., Danenberg H.D., Golomb G. Lipophilic drug loaded nanospheres prepared by nanoprecipitation: effect of formulation variables on size, drug recovery and release kinetics. Journal Controlled Release 2002, 83(3):389-400.
119. Barrat G., Courraze G., Couvreur C., Fattal E., Gref R.D.L., Legrand P., Ponchel G., Vauthier C. Polymeric micro- and nanoparticles as drug carriers. Polymeric Biomaterials 2000, 753-781. Marcel Dekker, New York. S. Dumitriu (Ed.).
120. Nakache E., Poulain N., Candau F., Orecchioni A.M., Irache J.M. Biopolymer and polymer nanoparticles and their biomedical applications. Handbook of Nanostructured Materials and Nanotechnology 2000, 577-635. Academic Press, New York. H.S. Nalwa (Ed.).
121. Hans M.L., Lowman A.M. Biodegradable nanoparticles for drug delivery and targeting. Current Opinion in Solid State and Materials Science 2002, 6(4):319-327.
122. Sekhara Rao G.C., Kumar M.S., Mathivanan N., Bhanoji Rao M.E. Nano-suspensions as the most promising approach in nanoparticulate drug delivery systems. Phamazie 2004, 59(1):5-9.
123. Astete C.E., Sabliov C.M. Synthesis and characterization of PLGA nanoparticles. Journal of Biomaterial Sciences - Polymer Edition 2006, 17(3):247-289.
124. Allemann E., Gurny R., Doelker E. Drug-loaded nanoparticles - preparation methods and drug targeting issues. European Journal of Pharmceutics and Biopharmaceutics 1993, 39(5):173-191.
125. Hiremath S.R.R., Hota A. Nanoparticles as drug delivery systems. Indian Journal of Pharmaceutical Sciences 1999, 61(2):69-75.
126. Quintanar-Guerrero D., Allemann E., Fessi H., Doelker E. Preparation techniques and mechanisms of formation of biodegradable nanoparticles from preformed polymers. Drug Development and Industrial Pharmacy 1998, 24(12):1113-1128.
127. Moghimi S.M., Hunter A.C., Murray J.C. Long-circulating and target-specific nanoparticles: theory to practice. Pharmacological Reviews 2001, 53(2):283-318.
128. Panyam J., Labhasetwar V. Biodegradable nanoparticles for drug and gene delivery to cells and tissue. Advanced Drug Delivery Reviews 2003, 55(3):329-347.
129. Avgoustakis K. Pegylated poly(lactide) and poly(lactide-co-glycolide) nanoparticles: preparation, properties and possible applications in drug delivery. Curr Drug Deliv 2004, 1(4):321-333.
130. Bala I., Hariharan S., Kumar M.N. PLGA nanoparticles in drug delivery: the state of the art. Critical Reviews in Therapeutic Drug Carrier Systems 2004, 21(5):387-422.
131. Alexis F. Factors affecting the degradation and drug-release mechanism of poly(lactic acid) and poly[(lactic acid)-co-(glycolic acid)]. Polym Int 2005, 54(1):36-46.
132. Quintanar-Guerrero D., Allemann E., Doelker E., Fessi H. A mechanistic study of the formation of polymer nanoparticles by the emulsification-diffusion technique. Colloid Polym Sci 1997, 275(7):640-647.
133. Konan Y.N., Cerny R., Favet J., Berton M., Gurny R., Allemann E. Preparation and characterization of sterile sub-200 nm meso-tetra(4-hydroxylphenyl)porphyrin-loaded nanoparticles for photodynamic therapy. European Journal of Pharmceutics and Biopharmaceutics 2003, 55(1):115-124.
134. Lee S.J., Jeong J.R., Shin S.C., Kim J.C., Chang Y.H., Lee K.H., Kim J.D. Magnetic enhancement of iron oxide nanoparticles encapsulated with poly(D,L-latide-co-glycolide). Colloids and Surfaces A - Physicochemical and Engineering Aspects 2005, 255(1-3):19-25.
135. Kumar R.M.N., Bakowsky U., Lehr C.M. Preparation and characterization of cationic PLGA nanospheres as DNA carriers. Biomaterials 2004, 25(10):1771-1777.
136. Kumar R.M.N., Mohapatra S.S., Kong X., Jena P.K., Bakowsky U., Lehr C.M. Cationic poly(lactide-co-glycolide) nanoparticles as efficient in vivo gene transfection agents. Journal of Nanoscience and Nanotechnology 2004, 4(8):990-994.
137. Ahlin P., Kristl J., Kristl A., Vrecer F. Investigation of polymeric nanoparticles as carriers of enalaprilat for oral administration. International Journal of Pharmaceutics 2002, 239(1-2):113-120.
138. Kwon H.Y., Lee J.Y., Choi S.W., Jang Y.S., Kim J.H. Preparation of PLGA nanoparticles containing estrogen by emulsification-diffusion method. Colloids and Surfaces A - Physicochemical and Engineering Aspects 2001, 182(1-3):123-130.
139. Konan Y.N., Gurny R., Allemann E. Preparation and characterization of sterile and freeze-dried sub-200 nm nanoparticles. International Journal of Pharmaceutics 2002, 233(1-2):239-252.
140. Zweers M.L., Engbers G.H., Grijpma D.W., Feijen J. In vitro degradation of nanoparticles prepared from polymers based on DL-lactide, glycolide and poly(ethylene oxide). Journal Controlled Release 2004, 100(3):347-356.
141. Eley J.G., Pujari V.D., Mclane J. Poly(lactide-co-glycolide) nanoparticles containing coumarin-6 for suppository delivery: in vitro release profile and in vivo tissue distribution. Drug Delivery 2004, 11(4):255-261.
142. Prakobvaitayakit M., Nimmannit U. Optimization of polylactic-co-glycolic acid nanoparticles containing itraconazole using 2(3) factorial design. AAPS PharmSciTech 2003, 4(4):1-9.
143. Govender T., Stolnik S., Garnett M.C., Illum L., Davis S.S. PLGA nanoparticles prepared by nanoprecipitation: drug loading and release studies of a water soluble drug. Journal Controlled Release 1999, 57(2):171-185.
144. Csaba N., Caamano P., Sanchez A., Dominguez F., Alonso M.J. PLGA: poloxamer and PLGA:poloxamine blend nanoparticles: new carriers for gene delivery. Biomacromolecules 2005, 6(1):271-278.
145. Niwa T., Takeuchi H., Hino T., Kunou N., Kawashima Y. Preparations of biodegradable nanospheres of water-soluble and insoluble drugs with D,L-lactide glycolide copolymer by a novel spontaneous emulsification solvent diffusion method, and the drug release behavior. Journal Controlled Release 1993, 25(1-2):89-98.
146. Ameller T., Marsaud V., Legrand P., Gref R., Renoir J.M. Pure anti-estrogen RU 58668-loaded nanospheres: morphology, cell activity and toxicity studies. Euopean Journal of Pharmaceutical Sciences 2004, 21(2-3):361-370.
147. Oster C.G., Wittmar M., Unger F., Barbu-Tudoran L., Schaper A.K., Kissel T. Design of amine-modified graft polyesters for effective gene delivery using DNA-loaded nanoparticles. Pharm Res 2004, 21(6):927-931.
148. Saxena V., Sadoqi M., Shao J. Indocyanine green-loaded biodegradable nanoparticles: preparation, physicochemical characterization and in vitro release. International Journal of Pharmaceutics 2004, 278(2):293-301.
149. Csaba N., Gonzalez L., Sanchez A., Alonso M.J. Design and characterisation of new nanoparticulate polymer blends for drug delivery. Journal of Biomaterials Science - Polymer Edition 2004, 15(9):1137-1351.
150. Panagi Z., Beletsi A., Evangelatos G., Livaniou E., Ithakissios D.S., Avgoustakis K. Effect of dose on the biodistribution and pharmacokinetics of PLGA and PLGA-mPEG nanoparticles. International Journal of Pharmaceutics 2001, 221(1-2):143-152.
151. De Jaeghere F., Doelker E., Gurny R. Nanoparticles. Encyclopedia of Control Drug Delivery 1999, 641-664. John Wiley & Sons, New York. E. Mathiowitz (Ed.).
152. Alex R., Bodmeier R. Encapsulation of water-soluble drugs by a modified solvent evaporation method. I. Effect of process and formulation variables on drug entrapment. J Microencapsul 1990, 7(3):347-355.
153. Takada S., Yamagata Y., Misaki M., Taira K., Kurokawa T. Sustained release of human growth hormone from microcapsules prepared by a solvent evaporation technique. Journal Controlled Release 2003, 88(2):229-242.
154. Obeidat W.M., Price J.C. Viscosity of polymer solution phase and other factors controlling the dissolution of theophylline microspheres prepared by the emulsion solvent evaporation method. J Microencapsul 2003, 20(1):57-65.
155. Park S.J., Kim S.H. Preparation and characterization of biodegradable poly(L-lactide)/poly(ethylene glycol) microcapsules containing erythromycin by emulsion solvent evaporation technique. J Colloid Interf Sci 2004, 271(2):336-341.
156. Mohammed F.A., Hassan M.A. Formulation and evaluation of ciprofloxacin hydrochloride and norfloxacin microspheres prepared by an enhanced emulsion-solvent evaporation process. Stp Pharma Sci 2003, 13(5):319-327.
157. Lopez-Quintela M.A. Synthesis of nanomaterials in microemulsions: formation mechanisms and growth control. Curr Opin Colloid In 2003, 8(2):137-144.
158. Bouchemal K., Briancon S., Perrier E., Fessi H. Nano-emulsion formulation using spontaneous emulsification: solvent, oil and surfactant optimisation. International Journal of Pharmaceutics 2004, 280(1-2):241-251.
159. Schmitt V., Leal-Calderon F., Bibette J. Preparation of monodisperse particles and emulsions by controlled shear. Topics in Current Chemistry 2003, 227:195-215.
160. Zhao X., Goveas J.L. Size selection in viscoelastic emulsions under shear. Langmuir 2001, 17(13):3788-3791.
161. Panyam J., Williams D., Dash A., Leslie-Pelecky D., Labhasetwar V. Solid-state solubility influences encapsulation and release of hydrophobic drugs from PLGA/PLA nanoparticles. Journal of Pharmaceutical Sciences 2004, 93(7):1804-1814.
162. Pietzonka P., Walter E., Duda-Johner S., Langguth P., Merkle H.P. Compromised integrity of excised porcine intestinal epithelium obtained from the abattoir affects the outcome of in vitro particle uptake studies. European Journal of Pharmaceutical Sciences 2002, 15(1):39-47.
163. Julienne M.C., Alonso M.J., Amoza J.L.G., Benoit J.P. Preparation of poly(D,L-lactide glycolide) nanoparticles of controlled particle-size distribution - application of experimental designs. Drug Development and Industrial Pharmacy 1992, 18(10):1063-1077.
164. Chung T.W., Huang Y.Y., Tsai Y.L., Liu Y.Z. Effects of solvent evaporation rate on the properties of protein-loaded PLLA and PDLLA microspheres fabricated by emulsion-solvent evaporation process. J Microencapsul 2002, 19(4):463-471.
165. Song C.X., Labhasetwar V., Murphy H., Qux, Humphrey W.R., Shebuski R.J., Levy R.J. Formulation and characterization of biodegradable nanoparticles for intravascular local drug delivery. Journal Controlled Release 1997, 43(2-3):197-212.
166. Pays K., Giermanska-Kahn J., Pouligny B., Bibette J., Leal-Calderon F. Coalescence in surfactant-stabilized double emulsions. Langmuir 2001, 17(25):7758-7769.
167. Pays K., Giermanska-Kahn J., Pouligny B., Bibette J., Leal-Calderon F. Double emulsions: how does release occur?. Journal Controlled Release 2002, 79(1-3):193-205.
168. Ficheux M.F., Bonakdar L., Leal-Calderon F., Bibette J. Some stability criteria for double emulsions. Langmuir 1998, 14(10):2702-2706.
169. Domb A.J., Bergelson L., Amselem S. Lipospheres for controlled delivery of substances. Microencapsulation: Methods and Industrial Applications 1996, 377-410. Marcel Dekker, New York. S. Benita (Ed.).
170. Aukunuru J.V., Ayalasomayajula S.P., Kompella U.B. Nanoparticle formulation enhances the delivery and activity of a vascular endothelial growth factor antisense oligonucleotide in human retinal pigment epithelial cells. The Journal of Pharmacy and Pharmacology 2003, 55(9):1199-1206.
171. Vandervoort J., Ludwig A. Biocompatible stabilizers in the preparation of PLGA nanoparticles: a factorial design study. International Journal of Pharmaceutics 2002, 238(1-2):77-92.
172. Dillen K., Weyenberg W., Vandervoort J., Ludwig A. The influence of the use of viscosifying agents as dispersion media on the drug release properties from PLGA nanoparticles. European Journal of Pharmceutics and Biopharmaceutics 2004, 58(3):539-549.
173. Prabha S., Labhasetwar V. Critical determinants in PLGA/PLA nanoparticle-mediated gene expression. Pharm Res 2004, 21(2):354-364.
174. Vandervoort J., Yoncheva K., Ludwig A. Influence of the homogenisation procedure on the physicochemical properties of PLGA nanoparticles. Chemical & Pharmaceutical Bulletin 2004, 52(11):1273-1279.
175. Sahoo S.K., Panyam J., Prabha S., Labhasetwar V. Residual polyvinyl alcohol associated with poly (D,L-lactide-co-glycolide) nanoparticles affects their physical properties and cellular uptake. Journal Controlled Release 2002, 82(1):105-114.
176. Dillen K., Vandervoort J., Van Den Mooter G., Verheyden L., Ludwig A. Factorial design, physicochemical characterisation and activity of ciprofloxacin-PLGA nanoparticles. International Journal of Pharmaceutics 2004, 275(1-2):171-187.
177. Mu L., Feng S.S. A novel controlled release formulation for the anticancer drug paclitaxel (Taxol): PLGA nanoparticles containing vitamin E TPGS. Journal Controlled Release 2003, 86(1):33-48.
178. Jeon H.J., Jeong Y.I., Jang M.K., Park Y.H., Nah J.W. Effect of solvent on the preparation of surfactant-free poly(DL-lactide-co-glycolide) nanoparticles and nor floxacin release characteristics. International Journal of Pharmaceutics 2000, 207(1-2):99-108.
179. Lemarchand C., Couvreur P., Besnard M., Costantini D., Gref R. Novel polyester-polysaccharide nanoparticles. Pharm Res 2003, 20(8):1284-1292.
180. Li Y., Pei Y., Zhang X., Guz, Zhou Z., Yuan W., Zhou J., Zhu J., Gao X. PEGylated PLGA nanoparticles as protein carriers: synthesis, preparation and biodistribution in rats. Journal Controlled Release 2001, 71(2):203-211.
181. Beletsi A., Leontiadis L., Klepetsaniis P., Ithakissios D.S., Avgoustakis K. Effect of preparative variables on the properties of poly(DL-lactide-co-glycolide)-methoxypoly(ethyleneglycol) copolymers related to their application in controlled drug delivery. International Journal of Pharmaceutics 1999, 182(2):187-197.
182. Fonseca C., Simoes S., Gaspar R. Paclitaxel-loaded PLGA nanoparticles: preparation, physicochemical characterization and in vitro anti-tumoral activity. Journal Controlled Release 2002, 83(2):273-286.
183. Lamprecht A., Ubrich N., Yamamoto H., Schafer U., Takeuchi H., Maincent P., Kawashima Y., Lehr C.M. Biodegradable nanoparticles for targeted drug delivery in treatment of inflammatory bowel disease. The Journal of Pharmacology and Experimental Therapeutics 2001, 299(2):775-781.
184. Lee W.K., Park J.Y., Yang E.H., Suh H., Kim S.H., Chung D.S., Choi K., Yang C.W., Park J.S. Investigation of the factors influencing the release rates of cyclosporin A-loaded micro- and nanoparticles prepared by high-pressure homogenizer. Journal Controlled Release 2002, 84(3):115-123.
185. Mainardes R.M., Evangelista R.C. PLGA nanoparticles containing praziquantel: effect of formulation variables on size distribution. International Journal of Pharmaceutics 2005, 290(1-2):137-144.
186. Win K.Y., Feng S.S. Effects of particle size and surface coating on cellular uptake of polymeric nanoparticles for oral delivery of anticancer drugs. Biomaterials 2005, 26(15):2713-2722.
187. Zhang Y., Zhuo R.X. Synthesis and drug release behavior of poly (trimethylene carbonate)-poly (ethylene glycol)-poly (trimethylene carbonate) nanoparticles. Biomaterials 2005, 26(14):2089-2094.
188. Avgoustakis K., Beletsi A., Panagi Z., Klepetsanis P., Karydas A.G., Ithakissios D.S. PLGA-mPEG nanoparticles of cisplatin: in vitro nanoparticle degradation, in vitro drug release and in vivo drug residence in blood properties. Journal Controlled Release 2002, 79(1-3):123-135.
189. Allemann E., Leroux J.C., Gurny R., Doelker E. In vitro extended-release properties of drug-loaded poly(DL-lactic acid) nanoparticles produced by a salting-out procedure. Pharm Res 1993, 10(12):1732-1737.
190. Prabha S., Zhou W.Z., Panyam J., Labhasetwar V. Size-dependency of nanoparticle-mediated gene transfection: studies with fractionated nanoparticles. International Journal of Pharmaceutics 2002, 244(1-2):105-115.
191. Panyam J., Dali M.M., Sahoo S.K., Maw, Chakravarthi S.S., Amidon G.L., Levy R.J., Labhasetwar V. Polymer degradation and in vitro release of a model protein from poly(D,L-lactide-co-glycolide) nano-and microparticles. Journal Controlled Release 2003, 92(1-2):173-187.
192. Gopferich A. Polymer degradation and erosion: mechanisms and applications. European Journal of Pharmceutics and Biopharmaceutics 1996, 42(1):1-11.
193. Chung J.E., Yokoyama M., Okano T. Inner core segment design for drug delivery control of thermo-responsive polymeric micelles. Journal Controlled Release 2000, 65(1-2):93-103.
194. Chung J.E., Yokoyama M., Yamato M., Aoyagi T., Sakurai Y., Okano T. Thermo-responsive drug delivery from polymeric micelles constructed using block copolymers of poly(N-isopropylacrylamide) and poly(butylmethacrylate). Journal Controlled Release 1999, 62(1-2):115-127.
195. Giacomelli C., Le Men L., Borsali R., Lai-Kee-Him J., Brisson A., Armes S.P., Lewis A.L. Phosphorylcholine-based pH-responsive diblock copolymer micelles as drug delivery vehicles: light scattering, electron microscopy, and fluorescence experiments. Biomacromolecules 2006, 7(3):817-828.
196. Gillies E.R., Frechet J.M. pH-Responsive copolymer assemblies for controlled release of doxorubicin. Bioconjugate Chemistry 2005, 16(2):361-368.
197. Kamada H., Tsutsumi Y., Yoshioka Y., Yamamoto Y., Kodaira H., Tsunoda S., Okamoto T., Mukai Y., Shibata H., Nakagawa S., Mayumi T. Design of a pH-sensitive polymeric carrier for drug release and its application in cancer therapy. Clinical Cancer Research 2004, 10(7):2545-2550.
198. Xu P., Van Kirk E.A., Murdoch W.J., Zhan Y., Isaak D.D., Radosz M., Shen Y. Anticancer efficacies of cisplatin-releasing pH-responsive nanoparticles. Biomacromolecules 2006, 7(3):829-835.
199. Redhead H.M., Davis S.S., Illum L. Drug delivery in poly(lactide-co-glycolide) nanoparticles surface modified with poloxamer 407 and poloxamine 908: in vitro characterisation and in vivo evaluation. Journal Controlled Release 2001, 70(3):353-363.
200. Yoo H.S., Lee K.H., Oh J.E., Park T.G. In vitro and in vivo anti-tumor activities of nanoparticles based on doxorubicin-PLGA conjugates. Journal Controlled Release 2000, 68(3):419-431.